You searched for ""

London, UK – 30/01/2026: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines, today announced that its partner Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining…

Progynova® (estradiol valerate) and Cyclo-Progynova® (estradiol valerate and norgestrel or levonorgestrel) are marketed in over 30 countries across EMEAIlomedin® (IV infusion iloprost) a Specialty Brand for Cardiovascular Disorders Including Thromboangiitis Obliterans1, a rare condition, is sold in over 30 markets across EMEA and APACThese acquisitions…

REYKJAVIK, ICELAND and LONDON, UK (November 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare…

REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare…

Zavesca® (miglustat) is sold in over 40 markets across APAC, EMEA, Latin America and North America.*This acquisition further strengthens ADVANZ PHARMA’s global specialty brands portfolio and focus on rare disease. London, UK – 13/10/2025: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company…

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar…

REYKJAVIK, ICELAND and LONDON, UK (September 22nd, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and…

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the…

REYKJAVIK, ICELAND and LONDON, UK (July 01, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare…

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma…

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today…

Testoviron® (testosterone enantate) strengthens ADVANZ PHARMA’s specialty medicines portfolioThe deal reinforces the partnership between ADVANZ PHARMA and BayerADVANZ PHARMA will provide access to the medicine through its European operations and global partner network London, UK – [18/06/2025] – ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the…

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025)…

London, UK – [15/05/2025] – ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines across Europe, Canada, and Australia, today announced the expansion of its existing partnership with PHARMATHEN, a leading pharmaceutical…

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (March 26, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and ADVANZ PHARMA, a…

London, UK – 04/12/2024: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines today announced the expansion of its specialty brands portfolio with the acquisition of certain APAC (excluding Japan and China) rights of…

The conditional marketing authorisation for OCALIVA® across the EU and EEA has been revoked with immediate effectADVANZ PHARMA is considering next steps, including options to enable continued access for patients London, UK – 27/11/2024: ADVANZ PHARMA Holdco Limited (ADVANZ PHARMA or the Company), a UK headquartered pharmaceutical company, today announces…

Atarax® (hydroxyzine dihydrochloride) and Nootropil® (piracetam) are sold in more than 30 countries across Europe, LATAM and APACThe acquisition leverages ADVANZ PHARMA’s commercial and medical footprint in Europe, as well as its global distribution partner networkThe acquisition further strengthens ADVANZ PHARMA’s global specialty brands portfolio London,…

REYKJAVIK, ICELAND and LONDON, UK (November 04, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and ADVANZ PHARMA, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today…

ADVANZ PHARMA releases its 2023-2024 ESG report reinforcing its commitment to sustainability.The report is structured across our three strategic ESG pillars: focusing on patients’ needs; ensuring sustainable and responsible operations and growth; and developing our people. London, UK – 04/10/2024: - ADVANZ PHARMA Holdco Limited ("ADVANZ PHARMA" or "the…

The European Commission’s decision to revoke the OCALIVA® conditional marketing authorisation has been suspended with immediate effect by Order of the President of the General Court of the European UnionThe conditional marketing authorisation for OCALIVA® remains valid in Europe until further notice from the General Court OCALIVA® remains fully available…

OCALIVA® is the only farnesoid X receptor (FXR) agonist for patients with PBC and, until now the only approved and available second-line treatment option in Europe ADVANZ PHARMA is considering all options to enable continued access for patients London, UK – 3 September 2024: - ADVANZ PHARMA Holdco Limited (ADVANZ PHARMA or the Company), a UK headquartered…

London, UK and Pune, INDIA – 27/08/2024: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia and Enzene Biosciences, a biopharmaceutical company specialising in the development and…

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, ICELAND and LONDON, UK (August 15, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…

London, UK – 01/07/2024: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered pharmaceutical company, acknowledges that the Committee for Medicinal Products for Human Use (“CHMP”) has recommended the European Commission should revoke the EU conditional marketing authorisation of OCALIVA® for 2nd line use in patients with the…

ADVANZ PHARMA secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeADVANZ PHARMA will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, ICELAND and LONDON, UK (June 18, 2024) — Alvotech (NASDAQ: ALVO), a global biotech…

The European Commission (EC) granted marketing authorisation for EXBLIFEP®Developed by Allecra, EXBLIFEP® will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra in 2022ADVANZ PHARMA is committed to improving patients’ lives by providing potent therapeutic…

The European Commission (EC) granted marketing authorisation for EXBLIFEP®Developed by Allecra, EXBLIFEP® will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra in 2022ADVANZ PHARMA is committed to improving patients’ lives by providing potent therapeutic…

EXBLIFEP® demonstrated in a phase III clinical trial significant superiority in the primary composite endpoint of clinical cure and microbiological eradication over piperacillin/tazobactam in patients with complicated urinary tract infections caused by gram negative bacteriaThe antibiotic drug was originally developed by Allecra Therapeutics up to Phase…

Androcur® (cyproterone acetate) is sold in more than 60 markets across Europe, Canada, APAC, MENA, and Latin AmericaThe acquisition leverages ADVANZ’s commercial and medical footprint in Europe, as well as its global distribution partner networkThe acquisition further strengthens ADVANZ’s global specialty brands portfolio London, UK – 07/11/2023: - ADVANZ…

ADVANZ PHARMA closes the acquisition of global rights to Tostran® from Kyowa KirinADVANZ PHARMA signs agreement to acquire Progynova® and Cyclo-Progynova® in selected countries in LatAm from BayerThe acquisitions further strengthen ADVANZ’s global specialty brands portfolioThe acquisitions leverage ADVANZ’s commercial and medical footprint in Europe, as…

ADVANZ PHARMA acquires exclusive rights to register and commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in the European Economic Area, the UK, Switzerland, Canada, Australia, and New ZealandDimerix to receive up to €138.5 million in upfront and milestone payments, plus royalties, comprising of;€6.5 million upfront…

London, UK – Monday 04 September, 2023: ADVANZ PHARMA Corp. Limited (“ADVANZ” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, is pleased to announce that we have signed an exclusive licensing and supply agreement with GP Pharm for a peptide specialty…

ADVANZ PHARMA releases its 2022-2023 ESG report highlighting its sustained progress on environmental, social, and governance topics.The report is structured across the three key pillars that are closely linked with the Company’s strategic priorities: focusing on patients’ needs; ensuring sustainable and responsible operations and growth; and developing our…

Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in Europe The agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and three additional early-stage undisclosed biosimilar candidates Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to…

The launch of Palmeux®/Paliperidone 1-month long-acting injection is supporting ADVANZ PHARMA’s mission to improve patients' lives by providing the specialty medicines they depend on. “The launch of Palmeux®/Paliperidone is a next step in the growth journey of ADVANZ. It follows the recent successful introduction of Mytolac®/Myrelez®/Lanreotide” said…

ADVANZ PHARMA secures exclusive rights to register and commercialise a proposed biosimilar to Novartis’ Xolair® (omalizumab) in the European Economic Area, the UK, Switzerland, Canada, Australia, and New ZealandADVANZ PHARMA will leverage its existing specialty and hospital platform in these markets to ensure successful commercialisation and patient…

ADVANZ PHARMA secures exclusive rights to register and commercialise AT-007, a Phase 3 development compound for the treatment of several rare neurological diseases, including Galactosemia and SORD Deficiency, in the European Economic Area, the UK, and SwitzerlandADVANZ PHARMA will leverage its existing specialty, hospital, and rare disease expertise and…

ADVANZ PHARMA completes the acquisition of a hospital anti-infective portfolio from Sanofi, including the brands Azactam™, Cefotax™, Claforan™, Oroken™, Rulid™, Suprax™, Wintriaxone™ and Colistimethate Sodique products.The acquisition further strengthens ADVANZ PHARMA’s specialty and hospital business in Europe and internationally and builds on its existing…

ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the prevention of surgical site infections in abdominal and cardiac surgeries in Europe, leveraging its specialty and hospital footprint PolyPid to potentially receive over $110 million in upfront and milestone payments LONDON, July [XX], 2022 /CNW/ - ADVANZ PHARMA Corp. Limited…

LONDON, [July 01], 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, today announced that it has successfully completed the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada,…

Acquisition to strengthen ADVANZ PHARMA’s position as a partner of choice for commercialisation of specialty and hospital pharmaceuticals in EuropeAgreement includes ex-U.S. rights to commercialise orphan drug Ocaliva® for PBC, a progressive autoimmune disease affecting the liver, and the acquisition of the majority of Intercept’s subsidiaries and…

London, April 1, 2022: In accordance with previous announced information, ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"), a pharmaceutical company with a strategic focus on specialty pharmaceuticals and specialty & hospital generics in Europe, today welcomes Steffen Wagner as its new CEO. Steffen joins from STADA, where he was a member of the Global…

Bringing quality medicines to patients is always the ultimate aim for companies within the pharmaceutical industry; however, the route and complexities in arriving at this point can sometimes be underestimated or understated, especially within the off-patent sector. There are a huge number of factors at play within this process, from the development of…

NOT FOR PUBLICATION IN THE UNITED STATESCidron Aida Finco S.à r.l. Successful pricing of €175.0 million 5% Senior Secured Notes due 2028JANUARY 19,2022. 16:00 GMT. Cidron Aida Finco S.à r.l. (the “Issuer”) today announced the successful pricing of its offering (the “Notes Offering”) of €175.0 million in aggregate principal amount of euro-denominated 5%…

NOT FOR PUBLICATION IN THE UNITED STATESCidron Aida Finco S.à r.l. Proposed Offering of €150 million 5% Senior Secured Notes due 2028JANUARY 17, 2022. 09:00 GMT. Cidron Aida Finco S.à r.l. (the “Issuer”) today announced an intention to offer (the “Offering”), subject to market conditions, €150.0 million in aggregate principal amount of euro-denominated 5%…

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royaltiesADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom,…

LONDON, December 9, 2021 - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company committed to improving the lives of patients by enhancing the critical medicines they depend on, today launched its inaugural Environmental, Social & Governance (ESG) report. Key achievements highlighted in the report include: We…

Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas Stickler as new Chief Financial Officer LONDON, Nov. 18, 2021 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, today announced several changes in senior leadership roles as…

Norway, 11 November 2021 - ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, has today announced the launch of MYRELEZ® (lanreotide) in Norway, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours and symptoms…

Friday 17th September marks World Patient Safety Day, campaign for all stakeholders in the health care system to work together and share engagement to improve patient safety. We asked the Director of Global Patient Safety, Dr. Anju Agarwal, about the importance of patient safety and what it means to her.Patient safety forms the essential foundation of any…

Bielefeld, Germany, 15 July 2021 - ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, has today announced the launch of MYTOLAC® (lanreotide) in Germany, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours and…

Complete gender equality among employees is an aspiration for many companies, however, despite decades of progressive efforts, there is still a great deal of work to be done. At ADVANZ PHARMA, creating a gender equal working environment is a priority. We are committed to championing and empowering female employees and ensuring equal treatment and access to…

LONDON, UK, June 14, 2021: ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, today announced that it has entered into an agreement with Eisai Co., Ltd (Tokyo, “Eisai”) to acquire its European, Middle Eastern, Russian and Australian rights for the…

LONDON, UK, June 11, 2021: ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, is proud to announce that Kit Britten, VP for UK & Ireland Commercial, has been elected as chair of the British Generic Manufacturers Association (BGMA)’s Economic &…

The acquisition will bring significant investment and expertise to help fuel ADVANZ PHARMA’s growth, with the potential to bring further cost-savings to the NHS and wider European healthcare systems while enhancing choice and access to critical medicines globally. LONDON, June 01, 2021 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"),…

ADVANZ PHARMA’s Global Director of Commercial Excellence David Johnson outlines the company’s investment in its omnichannel excellence programme and commitment to employees through new ways of working. A rapid increase in the use of digital channels in recent years has meant healthcare professionals (HCPs) are consuming and communicating information in a…

Chief Corporate Development Officer, Guy Clark shares his thoughts on ADVANZ PHARMA’s growth and investment strategy and how ADVANZ positions itself as the ‘go-to’ partner for M&A. “Growth” is a word we tend to associate with the expansion of a company’s capital or assets organically over a prolonged period of time. However successful growth within the…

Eve-Anadel Coronado is a vibrant and valued member of the ADVANZ Women’s Network (AWN). The AWN provides a space for gender issues and equality to be discussed without judgement. A space where each member has a voice, where smart ideas are shared, and tangible solutions are offered by women who can relate to each other’s daily personal and professional…

On Rare Disease Day 2021, our Chief Medical Officer, Nick Warwick, shares his thoughts on what this means to him and of the importance of not overlooking patient needs.The past year has been a time for true reflection and readjustment for many of us. At ADVANZ PHARMA, we have made a shift in our strategic compass to focus more on enriching our portfolio…

Agnès Bassage joined the ADVANZ Women’s Network (AWN) when it was established in 2018. She has been integral to the development of the platform designed to support and empower our female workforce. As Head of HR for our Europe, United Kingdom & North America business, Agnès is right in her element. ADVANZ PHARMA strives to achieve a high level of…

Tim Churchill is Director of Global Quality at ADVANZ PHARMA, based in our London office. Last year, Tim became the first male member of the ADVANZ Women’s Network (AWN), a decision taken by the network in order to bring a male perspective into discussions around gender equality. For Tim, AWN membership gave him the chance to be directly involved in working…

The success of any company is driven by its people, and ADVANZ PHARMA is no different. Our teams are made up of people from all walks of life and backgrounds. We thrive in an environment where uniqueness is celebrated, but we are all united by the same passion, to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease…

Recent incidents have occurred involving person(s) falsely claiming to recruit on behalf of ADVANZ PHARMA. These communications are intended to deceive you. ADVANZ PHARMA does not permit any unauthorized recruitment and in the process does not seek or provide money or payments. ADVANZ PHARMA will not request personal information such as social security…

Last updated: 01 Aug 2023 AS USED HEREIN, THE TERMS “YOU” AND “USER” SHALL MEAN ANY VISITOR TO THE WEBSITE. PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY. This page sets out the terms and conditions of use ("Terms") which apply to Your use of www.advanzpharma.com and all other websites ("Website") operated by companies in the ADVANZ PHARMA group. BY…